50 likes | 233 Views
A. B. EGFR binding + D-K 6 L 9 lytic peptide. EGFR binding + Newly designed lytic peptide. YHWYGYTPQNVIGGG KL L LK L L KK LLK L LKKK. YHWYGYTPQNVIGGGLK L LK K L LK KLL K LL-NH 2. C. D. EGFR-D-K 6 L 9 peptide. EGFR-lytic peptide. [θ] (deg cm 2 dmol -1 ). Wave length (nm).
E N D
A B EGFR binding + D-K6L9 lytic peptide EGFR binding + Newly designed lytic peptide YHWYGYTPQNVIGGG KLLLKLLKKLLKLLKKK YHWYGYTPQNVIGGGLKLLKKLLKKLLKLL-NH2 C D EGFR-D-K6L9 peptide EGFR-lytic peptide [θ] (deg cm2 dmol-1) Wave length (nm) Wave length (nm) [θ] (deg cm2 dmol-1) PC SUVs PC SUVs PC/PS SUVs PC/PS SUVs Fig. S1. (A)-(D) Kohno et al.
A MRC-5 H322 ● EGFR-D-K6L9 ○ D-K6L9 Cell viability (% control) Peptide (mM) Peptide (mM) B ● EGFR-lytic ○ D-K6L9 BT-20 HC Cell viability (% control) Peptide (mM) Peptide (mM) Fig. S2. (A)-(B) Kohno et al.
A Start injection Stop injection 27mM-chimeric peptide Response 13mM-chimeric peptide 24mM-lytic peptide 12mM-lytic peptide B Time (s) H322 H322 MRC-5 Response Response 0.1mg/ml 0.1mg/ml 0.05mg/ml 0.05mg/ml 0.025mg/ml 0.025mg/ml C Time (s) Time (s) H322 MRC-5 0.1mg/ml Response Response 0.05mg/ml 0.025mg/ml Fig. S3. (A)-(C) Kohno et al. Time (s) Time (s)
D Fig. S3. (D) Kohno et al.
Lytic-TAMRA Calcein-green 50mm TAMRA-red 50mm DIC 50mm 0 min 2 min 5 min 10 min 20 min Fig. S4. Kohno et al.